By Fineline Cube 
US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its Emblaveo (aztreonam, avibactam). The drug is indicated for the treatment of adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.
Drug Profile
Emblaveo is the first β-lactam/β-lactamase inhibitor combination to cover all types of carbapenemase enzymes. The fixed-dose combination design provides broad-spectrum enzyme inhibition, including KPC carbapenemases, OXA-48 carbapenemases, and Metallo-β-lactamases (MBLs). This addresses a key limitation of existing β-lactamase inhibitors.-Fineline Info & Tech